Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Trial Profile

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 122 (Primary) ; AB-928 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Arcus Biosciences
  • Most Recent Events

    • 23 Sep 2019 According to an Arcus Biosciences media release, data from this trial will be presented in a poster display session at the 2019 European Society for Medical Oncology (ESMO) Annual Meeting (Barcelona, Spain from 27th Sep-1st Oct 2019).
    • 03 Jun 2019 Preliminary results from ongoing phase I studies (NCT03719326; NCT03720678; NCT03629756) assessing the safety, pharmacokinetics (PK), pharmacodynamics, and clinical activity of increasing doses of AB928 (75, 150, 200 mg orally once daily) in combination with: standard pegylated liposomal doxorubicin presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 29 May 2019 According to an Arcus Biosciences media release, preliminary data from data from the ongoing Phase 1 dose-escalation trials of AB928 (NCT03719326; NCT03720678; NCT03629756) will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 to June 4.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top